Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;14(1):e200240.
doi: 10.1212/CPJ.0000000000200240. Epub 2023 Dec 27.

Blepharoclonus in Parkinsonism

Affiliations

Blepharoclonus in Parkinsonism

Jason Margolesky et al. Neurol Clin Pract. 2024 Feb.

Abstract

Background and objectives: In clinical practice, we have observed that patients with Parkinson disease (PD) often have blepharoclonus, but its prevalence is not well described in the literature. Understanding the relative frequencies of blepharoclonus in PD and atypical parkinsonian syndromes may shed light on the diagnostic utility of this clinical sign. We aimed to assess (1) the frequency of blepharoclonus in patients with PD in a single-center cohort; (2) the association of blepharoclonus with disease stage, tremor severity, and non-motor symptoms; and (3) the frequency of blepharoclonus in synucleinopathy vs non-synucleinopathy-associated parkinsonism.

Methods: We prospectively enrolled 85 patients, 75 with PD and 10 with atypical parkinsonism. Blepharoclonus was considered present if eyelid fluttering was sustained for >5 seconds after gentle eye closure. For each patient, demographics were collected, and we completed selected questions from the MDS-UPDRS (Unified Parkinson's Disease Rating Scale) part 2, REM Sleep Behavior Disorder Questionnaire, and MDS-UPDRS part 3 tremor assessments and recorded the presence/absence of dyskinesia.

Results: 63 of 75 patients with PD (84%) had blepharoclonus. Among the 10 patients with atypical parkinsonism, 5 had synucleinopathy syndromes. Blepharoclonus was present in 3 of 5 patients with synucleinopathy and 0 of 5 patients with non-synucleinopathy-associated parkinsonian syndromes.

Discussion: Blepharoclonus is prevalent in our PD cohort, suggesting possible utility as a clinical marker for PD. The absence of blepharoclonus in a patient with parkinsonism may suggest a non-synucleinopathy (e.g., tauopathy). Analysis of a larger cohort of both PD and atypical parkinsonism would be needed to establish whether blepharoclonus distinguishes PD from atypical parkinsonism, or synucleinopathy from non-synucleinopathy.

PubMed Disclaimer

Conflict of interest statement

J. Margolesky reports research funding/salary support from NIH/NINDS. D.Shpiner reports support from the Parkinson Foundation. C. Luca received educational grants and consulting fees from Medtronic, Boston Scientific, and Abbott. H. Moore received compensation due to participation in Advisory Boards from Ipsen Pharma. He has received research funding/salary support from MODUS Outcomes LLC, TEVA Pharmaceuticals, Sage Therapeutics, Bukwang Pharmaceutical, Neurocrine Biosciences, CHDI Foundation, and Impax Laboratories LLC. He has received foundation grants from the American Parkinson's Disease Association (APDA) and the Huntington's Disease Society of America (HDSA). C. Singer received honoraria form the Movement Disorders Society and research support from the Parkinson's Foundation. J. Wuu reports research support from the NIH, ALSA, and MDA. I. Haq has consulted for compensation for Medtronics, Boston Scientific, and Abbott DBS. He has received research funding and/or salary support from the NINDS, NIA, NIMH, Parkinson's Foundation, American Parkinson's Foundation of America, Parkinson's Study Group, and the Michael J Fox Foundation. M. Benatar reports grants from the NIH, the Muscular Dystrophy Association, and the ALS Association; as well as consulting fees for Alector, Alexion, Annexon, Arrowhead, Biogen, Cartesian, Denali, Eli Lilly, Horizon, Immunovant, Novartis, Roche, Sanofi, Takeda, UCB, and UniQure. The University of Miami has licensed intellectual property to Biogen to support design of the ATLAS study. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

References

    1. Behrman S, Scott DF. Blepharoclonus provoked by voluntary eye closure. Mov Disord. 1988;3(4):326-328. doi:10.1002/mds.870030407 - DOI - PubMed
    1. Methawasin K, Bhidayasiri R, Phanthumchinda K, Kaufman L. Blepharoclonus: anatomical localization and etiological consideration. J Med Assoc Thai. 2014;97(9):977-981. - PubMed
    1. Gatto M, Micheli F, Pardal MF. Blepharoclonus and Parkinsonism associated with aqueductal stenosis. Mov Disord. 1990;5(4):310-313. doi:10.1002/mds.870050409 - DOI - PubMed
    1. Jacome DE. Blepharoclonus and Arnold-Chiari malformation. Acta Neurol Scand. 2001;104(2):113-117. doi:10.1034/j.1600-0404.2001.104002113.x - DOI - PubMed
    1. Medarametla S, Boraiah N, Raju S. A curious case of excessive winking. Mov Disord Clin Pract. 2021;8(6):947-949. doi:10.1002/mdc3.13254 - DOI - PMC - PubMed

LinkOut - more resources